Treatment of Recurrent Refractory Pediatric Pre-B Acute Lymphoblastic Leukemia Using Inotuzumab Ozogamicin Monotherapy Resulting in CD22 Antigen Expression Loss as a Mechanism of Therapy Resistance
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Pediatric Hematology/Oncology"
DOI: 10.1097/mph.0000000000001440
Abstract: Background: Inotuzumab ozogamicin is a novel antibody-drug conjugate that targets CD22, a common antigen on pre-B acute lymphoblastic leukemia cells. Observations: A 7-year-old boy with pre-B acute lymphoblastic leukemia in his second relapse was given… read more here.
Keywords: pre acute; acute lymphoblastic; lymphoblastic leukemia; inotuzumab ozogamicin ... See more keywords
A Pediatric Case of Treatment-related Myelodysplastic Syndrome While on Therapy for Pre-B Acute Lymphoblastic Leukemia
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Pediatric Hematology/Oncology"
DOI: 10.1097/mph.0000000000002613
Abstract: Background: Treatment-related myelodysplastic syndrome (t-MDS) is a rare late effect of cancer therapy. After alkylating agents, this typically occurs years after completion of therapy. Treatment of t-MDS in pediatrics is an allogeneic stem cell transplant,… read more here.
Keywords: pre acute; therapy; related myelodysplastic; treatment related ... See more keywords
Characterization of Philadelphia-like Pre-B Acute Lymphoblastic Leukemia: Experiences in Mexican Pediatric Patients
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms23179587
Abstract: Ph-like subtypes with CRLF2 abnormalities are frequent among Hispano–Latino children with pre-B ALL. Therefore, there is solid ground to suggest that this subtype is frequent in Mexican patients. The genomic complexity of Ph-like subtype constitutes… read more here.
Keywords: philadelphia like; pre acute; crlf2; characterization philadelphia ... See more keywords